Skip to content

The Effect of Functional Training with Blood Flow Restriction on Hormonal, Inflammatory, and Cognitive Health in Elderly Women

The effect of eight weeks of functional training with blood flow restriction on biochemical, functional, and cognitive factors in women: Single-blind, randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191123045478N4
Enrollment
45
Registered
2026-05-25
Start date
2026-06-15
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle mass reduction due to aging. Other specified disorders of muscle

Interventions

Intervention 1: First intervention group: This group performed functional training with blood flow restriction (BFR) for 8 weeks, totaling 24 sessions (three sessions per week). BFR pressure was initi

Sponsors

Kharazmi University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
60 Years to 75 Years

Inclusion criteria

Inclusion criteria: (a) healthy elderly women; (b) no history of smoking or use of other tobacco products; (c) no history of cardiovascular disease, including coronary artery disease, arrhythmia, or heart failure, as well as no metabolic or renal disorders; (d) no use of medications affecting blood pressure; (e) no neurological, muscular, or skeletal disorders; (f) completion of a health questionnaire; (g) no participation in regular functional training programs in the two years preceding the study; (h) not following a weight-loss diet; (i) no use of medications or supplements that could affect study outcomes in the three months before the study; (j) provision of written informed consent.

Exclusion criteria

Exclusion criteria: History of deep vein thrombosis (DVT), peripheral arterial disease, lymphedema, or clotting disordersHistory of syncope during exercise or blood flow restrictionActive cancer undergoing chemotherapy or radiotherapy within the last 6 months, Major lower extremity surgery within the past 12 monthsPeripheral neuropathy impairing lower limb sensationUse of anticoagulants (warfarin, rivaroxaban, apixaban) or antiplatelet agents (clopidogrel)Participation in another clinical trial within the past 3 monthsKnown latex allergyAny condition that, in the physician's opinion, would compromise participant safety or study integrity Uncontrolled hypertension (systolic =160 or diastolic =100 mmHg) Chronic kidney disease stage 4 or 5 Uncontrolled diabetes (HbA1c >8.5%) or uncontrolled thyroid disorders Severe osteoarthritis (grade 4) fracture within 6 months, or joint replacement within the last year Major lower extremity surgery within the past 12 months Peripheral neuropathy impairing lower limb sensation Use of anticoagulants (warfarin, rivaroxaban, apixaban) or antiplatelet agents (clopidogrel) Participation in another clinical trial within the past 3 months

Design outcomes

Primary

MeasureTime frame
GH. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Blood Sampling.;IGFBP3. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Blood Sampling.;IL-6. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Blood Sampling.;Cortisol. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Blood Sampling.;Testosterone. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Blood Sampling.;VEGF. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Blood Sampling.;CRP. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Blood Sampling.

Secondary

MeasureTime frame
MOCA. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Montreal Cognitive Assessment.;Stroop Test. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Stroop Test.;Corsi Block Test. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Corsi Block software and test.;Mini-Mental State Examination (MMSE). Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Mini-Mental Status Questionnaire (MMSE).;Upper Body Strength. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Hand Grip Strength Test.;Lower Body Strength. Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Squat Test.;Timed Up and Go (TUG). Timepoint: One day before the first session and 48 hours after the last training session. Method of measurement: Timed Up and Go (TUG) test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Shakoor

Alzahra University

eli-shakoor@yahoo.com+98 21 8569 2669

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026